Normally it goes up before and goes down after the speaking. Now otherwise ?

There’s onlusten one on that list so it’s not common

Where is this flying today?

Maybe look also to Acog, they already filed an NDA for Alz

Last time the expectations were high and the PPS went up, we know what happend. Now expections are low so PPS goes down. Time for a surprise ?!

I want to see the peer reviewed article now, this will be decisive

I would say keep calm en wait for
upcoming peer-reviewed journal.
We will know more then.

George, silencing can not be improved, see the PPS now.

Curieus if hé will answer

Everytime George expectations does not come true the PPS goes down, good for shorters. I have my concerns…,

https://c.newsnow.co.uk/A/1176024700?-17462:2765

We need more details on ALZ trials before the PPS will go up

Slides from 2 december and the conference call from today are on the website now

Will there be some PR before the webcast ?

It would be important to know who’s responsible for the info on the slides. Could it be Ariana ?
It must cleared up

Axsm agition is not the same as cognition , what’s most important ?

Eisai
When I read the PR from Eisai it seems that the decline eases
with 27% but still go further. There is no stop in declining and surely no reverse.

Nice, great job

Just listen to real experts. AF is not.

Big party for shorters but it won’t keep going that way

M. at least could give some information about the delay
in stead by YE or around the corner.

No premarket activity yet? Rare

9:30 am Using Precision Medicine in Clinical Trials to Advancing Therapeutics for both Degenerative & Rare Mitochondrial Diseases

Christopher Missling
President & Chief Executive Officer, Anavex Life Sciences Corp
Synopsis

Assessing clinical data with biomarker-correlated outcomes of ANAVEX2-73 (blarcamesine) in Alzheimer’s, Parkinson’s, and Rett Syndrome
Reviewing mechanistic analysis of involvement of mitochondrial function

9:30 am Using Precision Medicine in Clinical Trials to Advancing Therapeutics for both Degenerative & Rare Mitochondrial Diseases

Christopher Missling
President & Chief Executive Officer, Anavex Life Sciences Corp
Synopsis

Assessing clinical data with biomarker-correlated outcomes of ANAVEX2-73 (blarcamesine) in Alzheimer’s, Parkinson’s, and Rett Syndrome
Reviewing mechanistic analysis of involvement of mitochondrial function

https://mitochondria-targets.com/

Last day to buy at this prices?
We may see next Tuesday.

Game playing had started again.

In the new January presentation this is mentionned about Avatar

Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial – expected YE 2021

So results must come very soon, otherwise it would have been changed.

You don’t do such promotions without a very good reason.

There must for sure be a good reason why they would attend
2 conferences within a few days.

, they wouldn’t do if if there is no great opportunity.
Love to see the presentation

It would not be the first stock who’s PPS is down before great news
is coming.

It’s not because Sava and Anvs are down big in premarket Avxl must
also, nothing had changed for us. So it’s just the market, don’t sell, others
will buy with a big smile.

https://endpts.com/new-alzheimers-drug-approval-fallout-public-citizen-seeks-removal-of-fdas-woodcock-cavazzoni-and-dunn/

No volume premarket ?

I received it also for the first time, so it could indeed be important.

Indeed impressive presentation

This drug is for sure safe, that from Biogen also ?

There are 2 new 8K out, aim is upgrading the production of ampligen, something coming ?

This is surely not the first company with this problem,
it will be solved.